Company Focus
AbbVie
Latest AbbVie News
Pharmaceutical
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies.
Latest News & Features of interest to AbbVie
Biotechnology
Significant regulatory news last week included the US Food and Drug Administration (FDA) granting approval for Zevra Therapeutics’ Miplyffa, making it the first treatment for Niemann-Pick disease type C, although this was quickly followed by an FDA nod for Aqneursa, developed by privately-held rare disease specialist IntraBio, for the same condition. Additionally, Bristol Myers Squibb last week announced that the FDA has approved its schizophrenia treatment Cobenfy, previously called KarXT. On the research front, US drug developer IDEAYA Biosciences released new Phase II data on its investigational uveal melanoma drug darovasertib. And US biotech Wave Life Sciences announced positive Phase II data on its Duchenne muscular dystrophy candidate WVE-N531. Also of note, due to safety concerns, US pharma giant Pfizer announced it is withdrawing its sickle cell disease drug Oxbryta from the market. 29 September 2024
Biotechnology
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Pharmaceutical
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
Pharmaceutical
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Pharmaceutical
San Diego-based start-up 858 Therapeutics has raised $50 million in a series B financing round, led by Avidity Partners. 27 September 2024
Biotechnology
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Pharmaceutical
Texas-based Cassava Sciences was trading 13% lower in Friday’s pre-market trading. 27 September 2024
Pharmaceutical
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
Biosimilars
European Commission (EC) has issued a marketing authorization for FYB202/Otulfi, a biosimilar to Johnson & Johnson’s Stelara. 27 September 2024
Biotechnology
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
Latest In Brief for AbbVie
Pharmaceutical
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Latest Related Ones To Watch News
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
23 September 2024
16 September 2024
9 September 2024
9 September 2024
5 September 2024
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze